2026 Q1 -tulosraportti
19 päivää sittenTarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 3 148 | - | - | ||
| 276 881 | - | - | ||
| 223 119 | - | - | ||
| 27 900 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 14.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·21 t sittenWeak bid side, no demand and lots of sellers. That is the result of a lack of communication - and a lack of having something to communicate. In the presentation of the annual report (26:10) the CEO said: quote: "... there is no doubt that in '26 we will be more active on the communication side. We have more to communicate and we will also strive to keep the market as informed as possible... " :) Half of the year has almost passed and nothing of relevance has been communicated. The stock has fallen 30 % since then and management merely silently watches as liquidity slowly disappears. In PEG's capital-dependent situation, I don't understand why they don't understand how vital it is to keep "the pot boiling" and see to it that some of the KPIs are achieved that can bring back confidence in the stock and the company ....... and management.
·20 t sittenCompletely agree but had to buy a bit extra at 0.068. That's quite a low price considering what the pipeline after all has to offer. Big lottery ticket, but one positive piece of news, and we could see much higher levels than the current price, which certainly reflects all your reasonable criticisms.- ·28.5.They don't deliver on their promises - the new management started aggressively with a strategy of renewed focus on shareholder value. They have consistently disappointed regarding when partnerships or revenue would materialize. And regarding Portinho, where Tange in the presentation of the annual report on 25/3 says that there will be news "around May". Now May is over, and yes, "around May" can be both a narrow or a broad definition. But credibility is completely gone if we suddenly find ourselves on the other side of summer and there is still no news on the matter. And news, beyond, worthless and high-flying statements without factual value for shareholders.
·20.5.I think the market overlooks how big this news actually is, regarding the patent. Reponex now has: clinical proof-of-concept, with an expected European patent. A market with billion-dollar potential and a focus on partnerships instead of burning billions themselves. Nevertheless, PEG is still traded as if the pipeline is worthless. Honestly don't understand the disconnect.- ·18.3.I see the current share price drop in as a short-term market reaction – not an expression of the underlying value. That the company guides 0 kr. in revenue, I do not interpret negatively. On the contrary, it signals that they deliberately opt out of short-term agreements to instead focus on larger and more value-creating partnerships around their vaccine platforms. With two potential vaccines in the pipeline, it makes strategic sense to play the long game rather than to “sell too early”. At the same time, the divestment of Portinho seems to be progressing in the right direction, which reduces uncertainty on the balance sheet and strengthens the case over time. For me, this is about timing: the market prices in missing revenues now, while I am more looking at the potential value that can be realized through future licensing agreements. Therefore, I am holding my shares and see the current level as an expression of short-term noise rather than a change in the long-term potential.
- ·4.3.Positive Status (but can also fail) and based on the information below, I do not understand the drop. Reponex has received **regulatory approval to start a pivotal Phase 2 study with RNX-011 for the treatment of life-threatening peritonitis. The study is designed to provide data that large pharma partners request during licensing negotiations. The first patient is expected to be included in Q4 2025. Furthermore, a clinical study application has already been submitted earlier in 2025, and the protocol has been approved, but is undergoing strategic adjustment to sharpen the study design in relation to requirements from collaboration partners. RNX-051 has previously completed a Phase 2 proof-of-concept study with positive results: The primary endpoint in the study was reached, and treatment with RNX-051 significantly reduced biofilm in the intestinal mucosa and changed the immune cell response in the experiment — which is promising in the development towards a preventive/therapeutic effect. In 2025, PEG has planned and prepared a new clinical trial for RNX-051, and an application for a new study was sent to the authorities in the first half of 2025 (Q1/Q2). The company is in active and advanced dialogues with potential industry partners regarding RNX-051 - and the protocols for further studies are almost complete and are expected to be what potential licensing partners will require before an agreement.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
19 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21 t sittenWeak bid side, no demand and lots of sellers. That is the result of a lack of communication - and a lack of having something to communicate. In the presentation of the annual report (26:10) the CEO said: quote: "... there is no doubt that in '26 we will be more active on the communication side. We have more to communicate and we will also strive to keep the market as informed as possible... " :) Half of the year has almost passed and nothing of relevance has been communicated. The stock has fallen 30 % since then and management merely silently watches as liquidity slowly disappears. In PEG's capital-dependent situation, I don't understand why they don't understand how vital it is to keep "the pot boiling" and see to it that some of the KPIs are achieved that can bring back confidence in the stock and the company ....... and management.·20 t sittenCompletely agree but had to buy a bit extra at 0.068. That's quite a low price considering what the pipeline after all has to offer. Big lottery ticket, but one positive piece of news, and we could see much higher levels than the current price, which certainly reflects all your reasonable criticisms.
- ·28.5.They don't deliver on their promises - the new management started aggressively with a strategy of renewed focus on shareholder value. They have consistently disappointed regarding when partnerships or revenue would materialize. And regarding Portinho, where Tange in the presentation of the annual report on 25/3 says that there will be news "around May". Now May is over, and yes, "around May" can be both a narrow or a broad definition. But credibility is completely gone if we suddenly find ourselves on the other side of summer and there is still no news on the matter. And news, beyond, worthless and high-flying statements without factual value for shareholders.
- ·20.5.I think the market overlooks how big this news actually is, regarding the patent. Reponex now has: clinical proof-of-concept, with an expected European patent. A market with billion-dollar potential and a focus on partnerships instead of burning billions themselves. Nevertheless, PEG is still traded as if the pipeline is worthless. Honestly don't understand the disconnect.
- ·18.3.I see the current share price drop in as a short-term market reaction – not an expression of the underlying value. That the company guides 0 kr. in revenue, I do not interpret negatively. On the contrary, it signals that they deliberately opt out of short-term agreements to instead focus on larger and more value-creating partnerships around their vaccine platforms. With two potential vaccines in the pipeline, it makes strategic sense to play the long game rather than to “sell too early”. At the same time, the divestment of Portinho seems to be progressing in the right direction, which reduces uncertainty on the balance sheet and strengthens the case over time. For me, this is about timing: the market prices in missing revenues now, while I am more looking at the potential value that can be realized through future licensing agreements. Therefore, I am holding my shares and see the current level as an expression of short-term noise rather than a change in the long-term potential.
- ·4.3.Positive Status (but can also fail) and based on the information below, I do not understand the drop. Reponex has received **regulatory approval to start a pivotal Phase 2 study with RNX-011 for the treatment of life-threatening peritonitis. The study is designed to provide data that large pharma partners request during licensing negotiations. The first patient is expected to be included in Q4 2025. Furthermore, a clinical study application has already been submitted earlier in 2025, and the protocol has been approved, but is undergoing strategic adjustment to sharpen the study design in relation to requirements from collaboration partners. RNX-051 has previously completed a Phase 2 proof-of-concept study with positive results: The primary endpoint in the study was reached, and treatment with RNX-051 significantly reduced biofilm in the intestinal mucosa and changed the immune cell response in the experiment — which is promising in the development towards a preventive/therapeutic effect. In 2025, PEG has planned and prepared a new clinical trial for RNX-051, and an application for a new study was sent to the authorities in the first half of 2025 (Q1/Q2). The company is in active and advanced dialogues with potential industry partners regarding RNX-051 - and the protocols for further studies are almost complete and are expected to be what potential licensing partners will require before an agreement.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 3 148 | - | - | ||
| 276 881 | - | - | ||
| 223 119 | - | - | ||
| 27 900 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 14.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
2026 Q1 -tulosraportti
19 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 14.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21 t sittenWeak bid side, no demand and lots of sellers. That is the result of a lack of communication - and a lack of having something to communicate. In the presentation of the annual report (26:10) the CEO said: quote: "... there is no doubt that in '26 we will be more active on the communication side. We have more to communicate and we will also strive to keep the market as informed as possible... " :) Half of the year has almost passed and nothing of relevance has been communicated. The stock has fallen 30 % since then and management merely silently watches as liquidity slowly disappears. In PEG's capital-dependent situation, I don't understand why they don't understand how vital it is to keep "the pot boiling" and see to it that some of the KPIs are achieved that can bring back confidence in the stock and the company ....... and management.·20 t sittenCompletely agree but had to buy a bit extra at 0.068. That's quite a low price considering what the pipeline after all has to offer. Big lottery ticket, but one positive piece of news, and we could see much higher levels than the current price, which certainly reflects all your reasonable criticisms.
- ·28.5.They don't deliver on their promises - the new management started aggressively with a strategy of renewed focus on shareholder value. They have consistently disappointed regarding when partnerships or revenue would materialize. And regarding Portinho, where Tange in the presentation of the annual report on 25/3 says that there will be news "around May". Now May is over, and yes, "around May" can be both a narrow or a broad definition. But credibility is completely gone if we suddenly find ourselves on the other side of summer and there is still no news on the matter. And news, beyond, worthless and high-flying statements without factual value for shareholders.
- ·20.5.I think the market overlooks how big this news actually is, regarding the patent. Reponex now has: clinical proof-of-concept, with an expected European patent. A market with billion-dollar potential and a focus on partnerships instead of burning billions themselves. Nevertheless, PEG is still traded as if the pipeline is worthless. Honestly don't understand the disconnect.
- ·18.3.I see the current share price drop in as a short-term market reaction – not an expression of the underlying value. That the company guides 0 kr. in revenue, I do not interpret negatively. On the contrary, it signals that they deliberately opt out of short-term agreements to instead focus on larger and more value-creating partnerships around their vaccine platforms. With two potential vaccines in the pipeline, it makes strategic sense to play the long game rather than to “sell too early”. At the same time, the divestment of Portinho seems to be progressing in the right direction, which reduces uncertainty on the balance sheet and strengthens the case over time. For me, this is about timing: the market prices in missing revenues now, while I am more looking at the potential value that can be realized through future licensing agreements. Therefore, I am holding my shares and see the current level as an expression of short-term noise rather than a change in the long-term potential.
- ·4.3.Positive Status (but can also fail) and based on the information below, I do not understand the drop. Reponex has received **regulatory approval to start a pivotal Phase 2 study with RNX-011 for the treatment of life-threatening peritonitis. The study is designed to provide data that large pharma partners request during licensing negotiations. The first patient is expected to be included in Q4 2025. Furthermore, a clinical study application has already been submitted earlier in 2025, and the protocol has been approved, but is undergoing strategic adjustment to sharpen the study design in relation to requirements from collaboration partners. RNX-051 has previously completed a Phase 2 proof-of-concept study with positive results: The primary endpoint in the study was reached, and treatment with RNX-051 significantly reduced biofilm in the intestinal mucosa and changed the immune cell response in the experiment — which is promising in the development towards a preventive/therapeutic effect. In 2025, PEG has planned and prepared a new clinical trial for RNX-051, and an application for a new study was sent to the authorities in the first half of 2025 (Q1/Q2). The company is in active and advanced dialogues with potential industry partners regarding RNX-051 - and the protocols for further studies are almost complete and are expected to be what potential licensing partners will require before an agreement.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 | - | - | ||
| 3 148 | - | - | ||
| 276 881 | - | - | ||
| 223 119 | - | - | ||
| 27 900 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 573 407 | 573 407 | 0 | 0 |